@article{ecbbf331b42c4cab9db727d6a97ddaa6,
title = "Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines",
abstract = "These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on {"}Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer{"} was added to the NCCN Guidelines to assist with using these novel targeted agents.",
author = "Tuttle, {R. Michael} and Haddad, {Robert I.} and Ball, {Douglas W.} and David Byrd and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Megan Haymart and Carl Hoh and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Peter Kopp and Lamonica, {Dominick M.} and Lydiatt, {William M.} and Judith McCaffrey and Moley, {Jeffrey F.} and Lee Parks and Raeburn, {Christopher D.} and Ridge, {John A.} and Ringel, {Matthew D.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Sherman, {Steven I.} and Cord Sturgeon and Waguespack, {Steven G.} and Wang, {Thomas N.} and Wirth, {Lori J.} and Hoffmann, {Karin G.} and Miranda Hughes",
note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",
year = "2014",
month = dec,
day = "1",
doi = "10.6004/jnccn.2014.0169",
language = "English",
volume = "12",
pages = "1671--1680",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "12",
}